期刊文献+

左西孟旦对急性心肌梗死伴心力衰竭患者血流动力学的影响 被引量:25

Effect of levosimendan on hemodynamics in patients with acute myocardial infarction complicated with heart failure
原文传递
导出
摘要 目的:观察左西孟旦对急性心肌梗死伴心力衰竭患者血流动力学的影响。方法:将92例急性心肌梗死伴心力衰竭患者按照数字随机法分为对照组和观察组,对照组46例患者采用常规的治疗方式进行治疗,观察组46例患者在常规治疗基础上加以左西孟旦进行治疗,对2组的治疗后血流动力学中各项指标变化进行对比分析。结果:2组患者治疗前血流动力学中各项指标无明显差异(P>0.05),而治疗后观察组患者在各项指标的改善程度上显著高于对照组(P<0.05)。结论:临床采用左西孟旦治疗急性心肌梗死伴心力衰竭患者,能够明显改善患者血流动力学中各项指标,具有较高的临床应用价值,值得推广使用。 Objective:To observe the effect of levosimendan on hemodynamics in patients with acute myocardial infarction and heart failure.Method:The 92 patients were randomly divided into control group and observation group.In control group 46 cases were treated with conventional treatment.In observation group the 46 cases were treated with the conventional treatment plus levosimendan treatment.We comparative analyzed the changes in hemodynamics in two groups after treatment.Result:There was no significant difference between the two groups in the hemodynamic parameters before treatment(P〉0.05),while the observation group was significantly higher than the control group(P〈0.05).Conclusion:Levosimendan treatment can improve the index of hemodynamics in patients with acute myocardial infarction and heart failure.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2017年第11期1074-1076,共3页 Journal of Clinical Cardiology
关键词 心肌梗死 心力衰竭 左西孟旦 血流动力学 myocardial infarction heart failure levosimendan hemodynamics
  • 相关文献

参考文献12

二级参考文献91

  • 1秦绪营.左西孟旦对急性左心衰竭患者心功能及血流动力学的影响[J].中国药物经济学,2013,8(S3):218-219. 被引量:2
  • 2吴士礼,包宗明,史晓俊,王洪巨,张宁汝.急性冠脉综合征患者血浆脑钠素检测及其意义[J].中国心血管病研究,2006,4(4):278-280. 被引量:6
  • 3Lemos J, McGuire D, Drazner M, et al. B-type natriuretic piptide in cardiovascular disease J. Lancet,2003,362 (14) :316-322.
  • 4Lee SC, Stevens TL, Sandberg SM, et al. The potential of brainna- triuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail, 2002,8(3) :149-154.
  • 5Dec GW. Acute decompensated heart failure:the shrinking role of inotropic therapy. Am Coll Cordial,2005,46( 1 ) :65-67.
  • 6De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart, 2006,27 (16) : 1908-1920.
  • 7Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure-the PERSIST study. Eur J Heart Fail, 2008,10 ( 12 ) : 1246 -1254.
  • 8McMurray JJ, Pfeffer MA. Heart failure [ J ]. Lancet, 2005,365 (9474) :1877-1889.
  • 9Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifyingthe heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study[J]. Eur Heart J, 2004,25(18) :1614-1619.
  • 10Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for de- veloping congestive heart failure: the Framingham Heart Study [ J ]. Circulation, 2002,106 ( 24 ) :3068-3072.

共引文献173

同被引文献219

引证文献25

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部